Physician profile
Daniel E Appelbaum
NPI 1184775157
$262,234.39
in general payments reported to CMS, 2019-2025
5 companies · $102K in 2025
The $102K reported for 2025 was more than what 97% of Nuclear Radiology providers received nationally (typical 2025 total: $145).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $450 · 2021: $29.47 · 2022: $8,682 · 2023: $46K · 2024: $104K · 2025: $102K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $226K · Travel and Lodging: $17K · Consulting Fee: $5,156 · Food and Beverage: $4,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225,824.75 |
| Travel and Lodging | $16,860.50 |
| Consulting Fee | $5,156.25 |
| Food and Beverage | $4,331.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $252,757.87 | 2020-2025 | Pylarify |
| Novartis Pharmaceuticals Corporation | $5,307.52 | 2023-2024 | |
| Blue Earth Diagnostics | $4,100.00 | 2019-2022 | |
| Syndax Pharmaceuticals, INC. | $39.53 | 2025 | |
| Abbvie INC. | $29.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Appelbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.